Nicotine pouches are increasingly available in consumer markets, including community pharmacies in some countries. Their growing use raises an important public-health question: can these products help reduce smoking-related harm while avoiding the creation of new patterns of nicotine dependence?
A review published in the Journal of the American Pharmacists Association examines both possibilities. Authors Emmanuel Fashesin Souza and Keykavous Parang assess the available evidence on nicotine delivery, toxicant exposure, smoking cessation and initiation among people who have never used nicotine. Their findings highlight the importance of distinguishing potential benefits for adults who smoke from risks among younger and nicotine-naïve populations.
What the Evidence Shows About Relative Risk
The researchers reviewed 35 peer-reviewed articles selected from 214 records identified through searches covering January 2019 to April 2026. The review found that nicotine pouches deliver nicotine through absorption in the mouth, with slower nicotine uptake than combustible cigarettes. The authors also reported an abuse-liability profile comparable to nicotine replacement therapy.
Evidence from biomarker studies indicated lower exposure to harmful substances among people using nicotine pouches compared with continued cigarette smoking. These findings support the potential role of nicotine pouches as a lower-exposure alternative for adults who smoke. However, reduced toxicant exposure should not be interpreted as evidence that the products are harmless. The review emphasises that complete cessation of nicotine and tobacco use remains preferable from a health perspective.
Cessation Evidence and Youth Initiation
An important distinction concerns the difference between replacing cigarettes and demonstrating effectiveness as a smoking-cessation treatment. The authors found that no randomised controlled trial included in their review had demonstrated a statistically significant effect of nicotine pouches on smoking cessation. This does not establish that substitution cannot occur. It does, however, limit the strength of claims that nicotine pouches are effective cessation interventions.
The review also identifies increasing experimentation among young people as a significant concern. Flavoured products, tobacco-free marketing and social media exposure may contribute to nicotine initiation among individuals who would otherwise not use nicotine. Accidental ingestion by young children represents another emerging safety issue.
Together, these findings illustrate why population-level assessments must consider both the potential reduction in cigarette-related exposure among existing smokers and the possibility of new nicotine use among non-users.
Implications for Regulation and Pharmacy Practice
The authors identify pharmacists as important sources of information for consumers navigating these different risk profiles. Their position reflects a broader challenge for nicotine regulation: communicating relative risk accurately without encouraging initiation or overstating the evidence for cessation. For adults who continue smoking, information about differences in toxicant exposure may be relevant when considering alternatives. For young people and those who do not use nicotine, preventing initiation remains the priority.
Regulatory approaches should account for these distinct populations while maintaining appropriate standards for product safety, packaging and marketing. The review also identifies substantial evidence gaps. Long-term clinical outcomes remain uncertain, and further research is needed to understand how nicotine pouches affect smoking behaviour and public health in real-world settings.
For GINN, the findings reinforce the importance of evidence-based, risk-proportionate regulation.
Nicotine pouches should be assessed according to their characteristics, potential benefits and documented risks. Reduced exposure relative to cigarettes is relevant, but it does not remove the need for youth safeguards or stronger evidence on long-term outcomes. The challenge for policymakers is to recognise these differences while ensuring that regulatory decisions remain responsive to emerging scientific evidence.
Source
Souza, E. F., & Parang, K. (2026). Nicotine pouches: Harm reduction or initiation pathway? A pharmacy-focused review. Journal of the American Pharmacists Association, 66(6), 103517. https://www.japha.org/article/S1544-3191(26)00502-9/fulltext






